For the fiscal year ended June 30, 2020, calculate the following for Novak Pharmaceutical Industries. (Round answers to 2 decimal places, e.g. $2.45.) (a) Basic earnings per share. Basic earnings per share $ (b) Diluted earnings per share. Diluted earnings per share $
For the fiscal year ended June 30, 2020, calculate the following for Novak Pharmaceutical Industries. (Round answers to 2 decimal places, e.g. $2.45.) (a) Basic earnings per share. Basic earnings per share $ (b) Diluted earnings per share. Diluted earnings per share $
Intermediate Accounting: Reporting And Analysis
3rd Edition
ISBN:9781337788281
Author:James M. Wahlen, Jefferson P. Jones, Donald Pagach
Publisher:James M. Wahlen, Jefferson P. Jones, Donald Pagach
Chapter16: Retained Earnings And Earnings Per Share
Section: Chapter Questions
Problem 25E
Related questions
Question
Amy Dyken, controller at Novak Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Novak’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020.
Novak Pharmaceutical Industries
Selected Balance Sheet Information June 30, 2020 |
||
Long-term debt | ||
Notes payable, 10% |
$980,000
|
|
7% convertible bonds payable |
5,060,000
|
|
10% bonds payable |
5,910,000
|
|
Total long-term debt |
$11,950,000
|
|
Shareholders’ equity | ||
|
$1,125,000
|
|
Common stock, $1 par, 10,100,000 shares authorized, 1,010,000 shares issued and outstanding |
1,010,000
|
|
Additional paid-in capital |
4,060,000
|
|
|
6,120,000
|
|
Total shareholders’ equity |
$12,315,000
|
The following transactions have also occurred at Novak.
1. | Options were granted on July 1, 2019, to purchase 220,000 shares at $15 per share. Although no options were exercised during fiscal year 2020, the average price per common share during fiscal year 2020 was $20 per share. | |
2. | Each bond was issued at face value. The 7% convertible bonds will convert into common stock at 50 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2019. | |
3. | The preferred stock was issued in 2019. | |
4. | There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2020. | |
5. | The 1,010,000 shares of common stock were outstanding for the entire 2020 fiscal year. | |
6. | Net income for fiscal year 2020 was $1,480,000, and the average income tax rate is 20%. |
For the fiscal year ended June 30, 2020, calculate the following for Novak Pharmaceutical Industries. (Round answers to 2 decimal places, e.g. $2.45.)
(a) Basic earnings per share.
Basic earnings per share |
$
|
(b) Diluted earnings per share.
Diluted earnings per share |
$
|
Expert Solution
This question has been solved!
Explore an expertly crafted, step-by-step solution for a thorough understanding of key concepts.
This is a popular solution!
Trending now
This is a popular solution!
Step by step
Solved in 2 steps
Knowledge Booster
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, accounting and related others by exploring similar questions and additional content below.Recommended textbooks for you
Intermediate Accounting: Reporting And Analysis
Accounting
ISBN:
9781337788281
Author:
James M. Wahlen, Jefferson P. Jones, Donald Pagach
Publisher:
Cengage Learning
Cornerstones of Financial Accounting
Accounting
ISBN:
9781337690881
Author:
Jay Rich, Jeff Jones
Publisher:
Cengage Learning
College Accounting, Chapters 1-27
Accounting
ISBN:
9781337794756
Author:
HEINTZ, James A.
Publisher:
Cengage Learning,
Intermediate Accounting: Reporting And Analysis
Accounting
ISBN:
9781337788281
Author:
James M. Wahlen, Jefferson P. Jones, Donald Pagach
Publisher:
Cengage Learning
Cornerstones of Financial Accounting
Accounting
ISBN:
9781337690881
Author:
Jay Rich, Jeff Jones
Publisher:
Cengage Learning
College Accounting, Chapters 1-27
Accounting
ISBN:
9781337794756
Author:
HEINTZ, James A.
Publisher:
Cengage Learning,